Company to host conference call today at 4:30pm ET CAMPBELL, Calif. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- VIVUS , Inc. (NASDAQ: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with

VIVUS receives $2.5 million milestone payment CAMPBELL, Calif. , Aug. 05, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, announced today that its Korean marketing partner, Alvogen , has obtained marketing approval for Qsymia (phentermine and

CAMPBELL, Calif. , July 23, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the second quarter of 2019 after the market close on Tuesday, August 6, 2019 . The company will host a conference call beginning at

-Companies will also collaborate to develop additional PANCREAZE dose formulations and an advanced formulation with an extended shelf life- CAMPBELL, Calif. , June 26, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (“VIVUS”), a biopharmaceutical company, today announced an amendment to its

A 30% plus reduction in patient out of pocket expense for medication, on-line purchasing and direct home delivery better enable patients to initiate and maintain Qsymia therapy CAMPBELL, Calif. , June 11, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical

                -Post-marketing study designed to evaluate Qsymia as an approach to weight management in a growing patient population with significant unmet medical need- CAMPBELL, Calif. , May 28, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company,

CAMPBELL, Calif. and CHARLOTTE, N.C., May 15, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, and HarborPath Direct, Inc. , today announced a partnership to facilitate access to PANCREAZE ® (pancrelipase) Delayed Release Capsules for uninsured or

Company to host conference call today at 4:30pm ET CAMPBELL, Calif. , April 30, 2019 (GLOBE NEWSWIRE) -- VIVUS , Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients

CAMPBELL, Calif. , April 16, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2019 after the market close on Tuesday, April 30, 2019 . The company will host a conference call beginning at

March 14, 2019 (ACCESSWIRE via COMTEX) -- CAMPBELL, CA / ACCESSWIRE / March 14, 2019 / VIVUS, Inc. VVUS, -1.41% a biopharmaceutical company, today announced that the Ministry of Health of the Russian Federation has approved 50 mg, 100 mg and 200 mg tablets of avanafil for the treatment of erectile